Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.712 EUR -0.28%
Market Cap: 29.5m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note
Section:
 

Relative Value

The Relative Value of one CYAD stock under the Base Case scenario is 0.015 EUR. Compared to the current market price of 0.712 EUR, Celyad Oncology SA is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CYAD Relative Value
Base Case
0.015 EUR
Overvaluation 98%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

409.7
P/S
P/S
Price to Sales
409.7
vs History
58
vs Industry
14
Median 3Y
61.7
Median 5Y
158.4
Industry
7.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-2
Industry
21.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-1.8
Industry
22.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1.7
Industry
23.5
More Details
4.7
P/B
P/B
Price to Book Value
4.7
vs History
80
vs Industry
46
Median 3Y
2.1
Median 5Y
2.6
Industry
2.5
More Details
324.9
EV/S
EV/S
Enterprise Value to Sales
324.9
vs History
60
vs Industry
19
Median 3Y
30.6
Median 5Y
85
Industry
7.5
More Details
615.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
615.7
vs History
46
vs Industry
7
Median 3Y
0
Median 5Y
115.8
Industry
9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1.8
Industry
4.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1.7
Industry
4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-1
Industry
6.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-1
Industry
4.1
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
84
vs Industry
64
Median 3Y
0.9
Median 5Y
1.3
Industry
4.5
More Details

Multiples Across Competitors

CYAD Competitors Multiples
Celyad Oncology SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Celyad Oncology SA
XBRU:CYAD
29.5m EUR 409.7 -3.8 -3.3 -3
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 095 167.8 -181 060.7 -219 865.3 -217 356.4
US
Abbvie Inc
NYSE:ABBV
314B USD 5.7 61.8 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
140.1B USD 4.3 33.1 15.9 30.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.1B USD 4.1 913.4 10.1 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.8B USD 9.8 -216.3 21.3 22.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.3 -471.9 -513.9 -500.2
AU
CSL Ltd
ASX:CSL
136.1B AUD 5.7 31.9 19.8 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 5.7 16.8 15.3 17
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
35.9B EUR 17.1 -330.9 -156.7 -102
P/S Multiple
Revenue Growth P/S to Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average P/S: 3 463 408.8
409.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 095 167.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.3
8%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
1 849.3
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
7%
0.8
US
S
Seagen Inc
F:SGT
17.8
30%
0.6
NL
argenx SE
XBRU:ARGX
17.1
47%
0.4
P/E Multiple
Earnings Growth PEG
BE
Celyad Oncology SA
XBRU:CYAD
Average P/E: 211.4
Negative Multiple: -3.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 060.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.8
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.1
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
913.4
21%
43.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -216.3
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.9 N/A N/A
AU
CSL Ltd
ASX:CSL
31.9
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -330.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/EBITDA: 16.3
Negative Multiple: -3.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 865.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
15.9
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
13%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.9 N/A N/A
AU
CSL Ltd
ASX:CSL
19.8
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -156.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/EBIT: 21.3
Negative Multiple: -3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 356.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.2
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.2 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102 N/A N/A

See Also

Summary
CYAD intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYAD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYAD stock valuation using valuation multiples.
Wall Street Estimates
CYAD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYAD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 213,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.